Literature DB >> 14730333

Elderly age and prior autologous transplantation have a deleterious effect on survival following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results from the Spanish multicenter prospective trial.

M Gómez-Núñez1, R Martino, M D Caballero, J A Pérez-Simón, C Canals, M V Mateos, J Sarrá, A León, C Solano, J M Moraleda, A Urbano-Ispizua, J Besalduch, J S Miguel, J Sierra.   

Abstract

Over a 3-year period, 145 patients ineligible for myeloablative conditioning underwent reduced-intensity conditioning (RIC) hematopoietic stem cell transplantation (SCT) from an HLA-identical sibling in a prospective study. The median age was 54 years, 88 patients were male and 61 patients were beyond the early-intermediate phase of their disease. The 100-day probability of developing grade II-IV acute graft-versus-host disease (GVHD) was 34%, and the 1-year probability of developing chronic extensive GVHD was 41%. The 1-year probabilities of transplant-related mortality (TRM), overall (OS) and progression-free survival were 20, 60 and 52%, respectively. Multivariate analyses found a better OS in: (i) patients <60 years; and (ii) recipients of a first SCT; and a higher TRM in: (i) age >60 years, (ii) recipients of a prior autologous SCT, and (iii) an ECOG performance status >1. The 1-year TRM in patients with 0 or 1 and >2 of the above-mentioned adverse prognostic factors were 17 vs 53%, respectively (P<0.001). In summary, our study shows that elderly patients have a higher TRM following an RIC protocol. However, age by itself should not preclude these RIC transplants, since TRM appears to be unacceptably high only in the presence of additional adverse factors.

Entities:  

Mesh:

Year:  2004        PMID: 14730333     DOI: 10.1038/sj.bmt.1704379

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  8 in total

1.  Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation.

Authors:  Mohamed L Sorror; Rainer F Storb; Brenda M Sandmaier; Richard T Maziarz; Michael A Pulsipher; Michael B Maris; Smita Bhatia; Fabiana Ostronoff; H Joachim Deeg; Karen L Syrjala; Elihu Estey; David G Maloney; Frederick R Appelbaum; Paul J Martin; Barry E Storer
Journal:  J Clin Oncol       Date:  2014-08-25       Impact factor: 44.544

Review 2.  Patient selection for allogeneic hematopoietic cell transplantation (HCT): the evolution of HCT risk assessment.

Authors:  Lori Muffly
Journal:  Curr Hematol Malig Rep       Date:  2015-03       Impact factor: 3.952

3.  Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.

Authors:  Mohamed L Sorror; Michael B Maris; Rainer Storb; Frederic Baron; Brenda M Sandmaier; David G Maloney; Barry Storer
Journal:  Blood       Date:  2005-06-30       Impact factor: 22.113

4.  A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation.

Authors:  Philippe Armand; Haesook T Kim; Corey S Cutler; Vincent T Ho; John Koreth; Jerome Ritz; Edwin P Alyea; Joseph H Antin; Robert J Soiffer
Journal:  Biol Blood Marrow Transplant       Date:  2007-11-26       Impact factor: 5.742

Review 5.  Risk assessment before allogeneic hematopoietic cell transplantation for older adults with acute myeloid leukemia.

Authors:  Mohamed L Sorror; Frederick R Appelbaum
Journal:  Expert Rev Hematol       Date:  2013-10-02       Impact factor: 2.929

6.  Pretransplant comorbidities maintain their impact on allogeneic stem cell transplantation outcome 5 years posttransplant: a retrospective study in a single german institution.

Authors:  Jens M Chemnitz; Geothy Chakupurakal; Maya Bäßler; Udo Holtick; Sebastian Theurich; Alexander Shimabukuro-Vornhagen; Silke Leitzke; Michael S Von Bergwelt-Baildon; Christof Scheid
Journal:  ISRN Hematol       Date:  2014-03-05

7.  Survival of hematological patients after discharge from the intensive care unit: a prospective observational study.

Authors:  Teresa Bernal; Estefanía V Pardavila; Juan Bonastre; Isidro Jarque; Marcio Borges; Joan Bargay; Jose Ignacio Ayestarán; Josu Insausti; Pilar Marcos; Victor González-Sanz; Pablo Martínez-Camblor; Guillermo M Albaiceta
Journal:  Crit Care       Date:  2013-12-30       Impact factor: 9.097

8.  Allogeneic stem cell transplant in patients with acute myeloid leukemia and karnofsky performance status score less than or equal to 80%: A study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation (EBMT).

Authors:  Francesco Saraceni; Myriam Labopin; Edouard Forcade; Nicolaus Kröger; Gerard Socié; Riitta Niittyvuopio; Jan J Cornelissen; Hélène Labussière-Wallet; Didier Blaise; Goda Choi; Jenny L Byrne; Gaelle Guillerm; Tony Marchand; Jordi Esteve; Ali Bazarbachi; Bipin Savani; Attilio Olivieri; Arnon Nagler; Mohamad Mohty
Journal:  Cancer Med       Date:  2020-11-26       Impact factor: 4.452

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.